GlassScriptPhysician profile
Melisa Dawn Loving
NPI 1497255376
$4,352.57
in general payments reported to CMS, 2019-2025
37 companies · $96.77 in 2025
The $96.77 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $890 · 2022: $1,470 · 2023: $1,466 · 2024: $430 · 2025: $96.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,120.70 | 2021-2025 | |
| Novo Nordisk INC | $588.76 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Corium, LLC | $263.98 | 2022-2024 | Azstarys |
| Amgen INC. | $256.77 | 2021-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $215.72 | 2022-2024 | Farxiga, Bevespi Aerosphere, Breztri |
| Pfizer INC. | $171.05 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $138.15 | 2021-2022 | |
| Lilly USA, LLC | $129.65 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.42 | 2022-2023 | |
| Alkermes, INC. | $111.30 | 2022 | |
| Glaxosmithkline, LLC. | $107.18 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $105.56 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.04 | 2021-2023 | Tradjenta, Jardiance |
| Neurocrine Biosciences, INC. | $81.46 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $80.86 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisa Loving listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.